目的 探究达格列净联合利拉鲁肽治疗2型糖尿病患者的临床效果。方法 收集2017年1月—2019年4月在郑州人民医院治疗的2型糖尿病患者126例，随机分为对照组（63例）和治疗组（63例）。对照组口服盐酸二甲双胍片，0.5 g/次，3次/d，同时于睡前皮下注射利拉鲁肽注射液0.6 mg，1周后根据患者肠道反应增加至1.2 mg，1次/d。治疗组早餐前口服达格列净片，10 mg/次，1次/d；利拉鲁肽注射液的用法同对照组。两组患者治疗时间均为3个月。观察两组患者临床疗效，同时比较治疗前后两组患者糖化血红蛋白（HbA1c）、空腹血糖（FPG）、餐后2 h血糖（2 h PG）、体质量指数（BMI）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、对纤溶酶原激活物抑制物-1（PAI-1）和胱抑素C（CysC）水平。结果 治疗后，对照组和治疗组临床有效率分别为79.37%和93.65%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者HbA1c、FPG、2 h PG、BMI、IL-6、TNF-α、PAI-1、CysC均显著降低（P<0.05），且治疗组上述指标比对照组更低（P<0.05）。结论 达格列净联合利拉鲁肽治疗2型糖尿病患者效果显著，且不增加不良反应，降低发生糖尿病血管并发症的风险。

Objective To explore the therapeutic effect of daglitam combined with liraglutide in treatment of type 2 diabetes mellitus. Methods Patients (126 cases) with type 2 diabetes mellitus in Zhengzhou People's Hospital from January 2017 to April 2019 were randomly divided into control (63 cases) and treatment (63 cases) groups. Patients in the control group were po administered with Metformin Hydrochloride Tablets, 0.5 g/time, three times daily, at the same time, they were hypodermic injection administered with 0.6 mg of Liraglutide Injection, and the dose was increased to 1.2 mg based on intestinal reaction, once daily. Patients in the treatment group were po administered with Dapagliflozin Tablets, 10 mg/time, once daily. The usage of Lalutide Injection was the same as that of the control group. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the levels of HbA1c, FPG, 2 h PG, BMI, IL-6, TNF-α, PAI-1, and CysC in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 79.37% and 93.65% respectively, and there were differences between two groups (P<0.05). After treatment, the levels of HbA1c, FPG, 2 h PG, BMI, IL-6, TNF-α, PAI-1, and CysC in two groups were significantly decreased (P<0.05), and these indicators in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion The treatment effect of daglitam combined with liraglutide in treatment of type 2 diabetes mellitus is remarkable, and it does not increase the incidence of adverse reactions and reduce the risk of diabetic vascular complications.

R977

河南省医学科技攻关计划联合共建项目（2018020817）